Li L, et al. - This updated systemic review and meta-analysis tested the effectiveness of combination therapy with sorafenib plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC) patients via systematically reviewing PubMed, EMBASE, Scopus and the Cochrane Library to search for relevant studies published from January 1990 to May 2017. In terms of prolonged time to progression and disease control rate, combination therapy might be beneficial for unresectable HCC patients. Fatigue, hand-foot skin reaction, diarrhea and hypertension were the most common adverse events.